Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

计划入组 6 人 · 首次发布于 2016 年 11 月 21 日

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

计划入组 8 人 · 首次发布于 2015 年 4 月 29 日

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

计划入组 78 人 · 首次发布于 2018 年 11 月 21 日

Isocitrate dehydrogenase inhibitors (Daiichi Sankyo)

Enasidenib(Idhifa)

C₁₉H₁₇F₆N₇O

Ivosidenib(Tibsovo)

C₂₈H₂₂ClF₃N₆O₃ · Rx

FDA Approves Vorasidenib (Voranigo) for IDH-Mutant Grade 2 Glioma

CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver for IDH-Mutant Gliomas in India

European Regulators Recommend Approval of Vorasidenib for IDH-Mutant Grade 2 Glioma